Viron Therapeutics: A next-gen anti-viral tech firm, pioneering in Covid-19 prophylactics.
Location
Boston, MA, US
Founded
1990
Viron Therapeutics focuses on developing next-generation anti-viral technologies. The firm's primary investment is in its own research and development, particularly in the area of prophylactic treatments for infectious diseases such as COVID-19. Their lead product, Viron C1, is a prophylactic against COVID-19 currently under FDA review.
The company's approach leverages cutting-edge anti-viral technology to address urgent global health challenges. Viron Therapeutics aims to pioneer innovative solutions in the fight against viral infections, positioning itself at the forefront of therapeutic advancements in this critical field.
Viron - Classification
Also Known As
Viron Inc.
NAICS
540000Professional, Scientific, and Technical Services
541714Research and Development in Biotechnology (except Nanobiotechnology)
520000Finance and Insurance
541000Professional, Scientific, and Technical Services
541700Scientific Research and Development Services
541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
6000Depository Institutions
8700Engineering, Accounting, Research, Management, And Related Services
8730Research, Development, And Testing Services
8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
320000Manufacturing
325400Pharmaceutical and Medicine Manufacturing
620000Health Care and Social Assistance
325000Chemical Manufacturing
623000Nursing and Residential Care Facilities
325410Pharmaceutical and Medicine Manufacturing
325412Pharmaceutical Preparation Manufacturing
SIC
2800
Chemicals And Allied Products
8000Health Services
2830Drugs
8040Offices And Clinics Of Other Health Practitioners
2834Pharmaceutical Preparations
8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified